Outcomes of pregnancy in women exposed to VIBATIV at any time during pregnancy Once per trimester, 6-7 months gestation, and within 4 weeks after the estimated due date [clinicaltrials_resource:deaee28b9138d424c7913ef66aa32896]
Women treated with telavancin (any dose or duration) during pregnancy.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Outcomes of pregnancy in women exposed to VIBATIV at any time during pregnancy Once per trimester, 6-7 months gestation, and within 4 weeks after the estimated due date [clinicaltrials_resource:deaee28b9138d424c7913ef66aa32896]
Women treated with telavancin (any dose or duration) during pregnancy.
Bio2RDF identifier
deaee28b9138d424c7913ef66aa32896
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:deaee28b9138d424c7913ef66aa32896
measure [clinicaltrials_vocabulary:measure]
Outcomes of pregnancy in women exposed to VIBATIV at any time during pregnancy
time frame [clinicaltrials_vocabulary:time-frame]
Once per trimester, 6-7 months gestation, and within 4 weeks after the estimated due date
description
Women treated with telavancin (any dose or duration) during pregnancy.
identifier
clinicaltrials_resource:deaee28b9138d424c7913ef66aa32896
title
Outcomes of pregnancy in women ...... s after the estimated due date
@en
type
label
Outcomes of pregnancy in women ...... ee28b9138d424c7913ef66aa32896]
@en